Q1 EPS Estimate for Eli Lilly and Company Lowered by Analyst

Eli Lilly and Company (NYSE:LLY) – Zacks Research cut their Q1 2025 EPS estimates for shares of Eli Lilly and Company in a research report issued on Monday, December 9th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $4.69 per share for the quarter, down from their previous estimate of $4.70. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $13.21 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q3 2025 earnings at $6.18 EPS, Q4 2025 earnings at $6.71 EPS, FY2025 earnings at $22.80 EPS, Q1 2026 earnings at $6.13 EPS, Q2 2026 earnings at $6.89 EPS and FY2026 earnings at $29.49 EPS.

LLY has been the subject of several other reports. Sanford C. Bernstein started coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target for the company. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Citigroup boosted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Wolfe Research began coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Finally, Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Trading Down 1.7 %

Shares of LLY stock opened at $782.35 on Wednesday. The company has a market capitalization of $742.70 billion, a P/E ratio of 85.47, a price-to-earnings-growth ratio of 3.13 and a beta of 0.41. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The business’s 50 day moving average is $837.49 and its two-hundred day moving average is $871.40. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter last year, the business posted $0.10 earnings per share. The business’s revenue was up 20.4% on a year-over-year basis.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently bought and sold shares of the company. Lantz Financial LLC lifted its position in Eli Lilly and Company by 1.3% during the second quarter. Lantz Financial LLC now owns 1,236 shares of the company’s stock worth $1,119,000 after buying an additional 16 shares during the period. Cornerstone Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 18.5% in the second quarter. Cornerstone Wealth Management LLC now owns 1,887 shares of the company’s stock worth $1,708,000 after acquiring an additional 294 shares during the last quarter. Baader Bank Aktiengesellschaft grew its holdings in Eli Lilly and Company by 96.2% in the second quarter. Baader Bank Aktiengesellschaft now owns 7,988 shares of the company’s stock valued at $7,100,000 after purchasing an additional 3,917 shares during the period. Hengehold Capital Management LLC increased its position in Eli Lilly and Company by 13.4% during the second quarter. Hengehold Capital Management LLC now owns 524 shares of the company’s stock worth $475,000 after purchasing an additional 62 shares during the last quarter. Finally, Petredis Investment Advisors LLC raised its stake in Eli Lilly and Company by 0.4% during the second quarter. Petredis Investment Advisors LLC now owns 11,413 shares of the company’s stock worth $10,333,000 after purchasing an additional 40 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company announced that its Board of Directors has initiated a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. Eli Lilly and Company’s dividend payout ratio is currently 64.86%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.